Table 6.
Adjusted* hazard ratio (95% confidence interval) for end-stage renal disease, by albuminuria category
| Albumin:Creatinine Ratio (mg/g) | ||||
|---|---|---|---|---|
| <30 | 30–299 | 300–999 | ≥1,000 | |
| British Columbia | Reference | 2.42 (1.80, 3.26) | 7.58 (5.83, 9.86) | 12.91 (9.82, 16.95) |
| CRIB | Reference | 9.78 (2.35, 40.63) | 16.39 (3.95, 68.02) | 29.72 (7.18, 123.10) |
| MASTERPLAN | Reference | 4.14 (1.22, 14.04) | 5.28 (1.49, 18.72) | 18.87 (5.57, 63.91) |
| NephroTest | Reference | 2.55 (1.26, 5.13) | 10.40 (5.31, 20.37) | 21.38 (10.86, 42.08) |
|
| ||||
| Overall | Reference | 2. 87 (1. 91, 4. 34) | 7. 96 (6. 27, 10. 09) | 14. 61 (11. 16, 19. 13) |
|
| ||||
| Protein:Creatinine Ratio (mg/g) | ||||
| <50 | 50–499 | 500–1,499 | ≥1,500 | |
|
| ||||
| AASK | Reference | 5.63 (3.49, 9.10) | 19.26 (11.75, 31.57) | 34.60 (19.76, 60.58) |
| MDRD | Reference | 2.18 (1.60, 2.99) | 2.87 (2.06, 4.00) | 4.47 (3.14, 6.37) |
| MMKD | Reference | 1.77 (0.23, 13.82) | 4.03 (0.54, 30.23) | 4.30 (0.58, 31.74) |
|
| ||||
| Overall | Reference | 3.18 (1.40, 7.18) | 6.38 (1.34, 30.34) | 9.47 (1.81, 49.60) |
|
| ||||
| Dipstick Category | ||||
| −/± | + | ++ | +++ | |
|
| ||||
| Kaiser Permanente Northwest | Reference | 1.71 (0.76, 3.84) | 7.22 (4.21, 12.97) | 19.41 (11.06, 34.04) |
|
| ||||
| OVERALL | Reference | 2. 92(2. 08, 4. 10) | 7. 70(4. 52, 13. 10) | 15. 01(8. 36, 26. 95) |
*
Adjusted for age, sex, race, prior cardiovascular disease, smoking status, diabetes mellitus, systolic blood pressure, and serum total cholesterol concentration.
AASK: African American Study of Kidney Disease and Hypertension; CRIB: Chronic Renal Impairment in Birmingham; MASTERPLAN: Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practicioner; MDRD: Modification of Diet in Renal Disease; MMKD: Mild to Moderate Kidney Disease Study; REIN: Ramipril Efficacy in Nephropathy; REIN 2: Ramipril Efficacy in Nephropathy 2; Steno: Steno Type 1 Diabetes Study